Radiopharm Theranostics Q2 2026 Earnings Results & Report

Radiopharm Theranostics EPS Results

• Actual EPS: -$1.5750
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Radiopharm Theranostics Revenue Results

• Actual Revenue: $0.46 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Radiopharm Theranostics (NASDAQ:RADX) Limited is a clinical-stage biotechnology company focused on developing radiopharmaceuticals for the diagnosis and treatment of cancer. Its approach combines targeted molecules with radioactive isotopes to help identify tumors through medical imaging and deliver radiation directly to cancer cells.

The company’s pipeline includes diagnostic and therapeutic programs based on peptides, small molecules and antibodies. These programs are designed to address cancers with significant unmet medical needs, including solid tumors and other difficult-to-treat malignancies. Radiopharm’s development activities include preclinical research and clinical studies evaluating the safety, imaging performance and therapeutic potential of its candidates.

Radiopharm Theranostics is headquartered in Australia and conducts development activities through collaborations and clinical programs in international markets, including the United States. The company is led by Chief Executive Officer and Managing Director Paul Hopper. Its shares trade on the Australian Securities Exchange under the symbol RAD and on the Nasdaq under the symbol RADX.